Page - (000266) - in Biomedical Chemistry: Current Trends and Developments

Kulkarni, M. M.; McMaster, W. R.; Kamysz, E.; Kamysz, W.; Engman, D. M.; McGwire, B. S. (2006). The major surface-metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing. Molecular Microbiology, 62, 1484-1497. Ladner, R. C.; Sato, A. K.; Gorzelany, J.; de Sousa, M. (2004). Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discovery Today, 15, 525-529. Ladokhin, A. S.; White S. H. (2001). Protein chemistry at membrane interfaces: non-additivity of electrostatic and hydrophobic interactions. Journal of Molecular Biology, 309, 543-552. Lai, L.; Xu, Z.; Zhou, J.; Lee, K. D.; Amidon, G. L. (2008). Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. Journal of Biological Chemistry, 283, 9318-9327. Lal, R.; Sukbuntherng, J.; Tai, E. H.; Upadhyay, S.; Yao, F.; Warren, M. S.; Luo, W.; Bu, L.; Nguyen, S.; Zamora, J.; Peng, G.; Dias, T.; Bao, Y.; Ludwikow, M.; Phan, T.; Scheuerman, R. A.; Yan, H.; Gao, M.; Wu, Q. Q.; Annamalai, T.; Raillard, S. P; Koller, K.; Gallop, M. A.; Cundy, K. C. (2009). Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. Journal of Pharmacology and Experimental Therapy, 330, 911-921. Landowski, C. P.; Vig, B. S.; Song, X.; Amidon, G. L. (2005a). Targeted delivery to PEPT1 - overexpresssing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Molecular Cancer Therapeutics, 4, 659-667. Landowski, C. P.; Sang, X.; Lorenzi, P. L.; Hilfinger, J. M.; Amidon, G. L. (2005b). Floxuridine amino acid ester prodrugs: enhancing Cacol-2 permeability and resistance to glycosidic bond metabolism. Pharmaceutical Research, 22, 1510-1518. Larsen, S. W.; Ankersen, M.; Larsen, C. (2004). Kinetics of degradation and oil solubility of ester prodrug of a model dipeptide (Gly-Phe). European Journal of Pharmaceutical Sciences, 22, 399-408. Lehrer, R.; Barton, A.; Daher, K. A.; Harwig S. S. L.; Ganz T.; Selsted M. E. (1989). Interaction of human defensins with Escherichia coli. Journal of Clinical Investigation, 84, 553-561. Li, W. F.; Ma, G. X.; Zhou, X. X. (2006). Apidaecin-type peptides: biodiversity, structure-function relationships and mode of action. Peptides, 27, 2350-2359. Lin, C.-C.; Anseth, K. (2009). PEG Hydrogels for the Controlled Release of Biomolecules in Regenerative Medicine. Pharmaceutical Research, 26, 631-643. Lin, S., Lowman, H. B. (2003). Therapeutic peptides. Trends in Biotechnology, 21, 556-562. Lien, S.; Lowman, H. B. (2003). Therapeutic Peptides. Trends in Biotechnology, 21, 556-562. Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiríksdóttir, E.; Jiang, Y.; Sassian, M.; Ostlund, P.; Hällbrink, M.; Langel, Ü. (2006). Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochemical Pharmacology, 71, 416-425. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25. Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal Pharmacological and Toxicological Methods, 44, 235-249. Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today Technologies, 1, 337-341.